INTRODUCTION
Anxiety disorders are frequent (lifetime prevalence ranging between 5 and 25% of the population, and a 12-month prevalence ranging between 3.3 and 20.4%, worldwide) (Kessler et al., 2009) . When adjusted for methodological differences, current (3-month) prevalence is estimated at 7.3% worldwide (4.8-10.9%), ranging from 5.3% (3.5-8.1%) in African settings to 10.4% (7.0-15.5%) in Euro/Anglo settings (Baxter, Scott, Vos, & Whiteford, 2013) . Some anxiety disorders, in particular the phobias, social anxiety, and separation anxiety, have very early age of onset (median ages in the range of 5-10 years of age; Kessler et al., 2009) , whereas others (generalized anxiety disorder, panic disorder, and posttraumatic stress disorder (PTSD)) tend to have a later age-of-onset distributions (median 24-50), with much wider cross-national variation.
Because of their relatively high prevalence, their tendency toward chronicity and substantial comorbidity, anxiety disorders are associated with significant disability (Harter, Conway, & Merikangas, 2003; Saha, Stedman, Scott, & McGrath, 2013) . Anxiety disorders cause 10.4% of the Disability Adjusted Life Years (DALYs) lost due to neurological, mental, substance use disorders and account for 1.1% of the global burden of disease worldwide, that is, a total of 26,800,000
DALYs worldwide (Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015) . Anxiety disorders are also very costly. It has been estimated that the total costs of anxiety disorders were €74.4 billion for 30 European EU countries in 2010 (Gustavsson et al., 2011) .
Cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are effective treatments for anxiety disorders (Hoffman & Smits, 2008; Koen & Stein, 2011) . Therefore anxiety disorders are among the conditions that have been identified by the WHO for scaling up interventions for mental disorders (Chisholm et al., 2016; World Health Organization (WHO), 2017 ). Yet a number of barriers limit the effective treatment of anxiety disorders. First, they are often unrecognized. Recognition rates in primary care may be lower than 50% (Culpepper, 2003) . Using standardized case detection methods has been recommended to improve their recognition in primary settings (Culpepper, 2003; Olariu et al., 2015) . Structural and health system weaknesses, including scarce mental health and human services (WHO, 2010) as well as lack of awareness and costs of treatment (Ho, Hunt, & Li, 2008) and stigma perceived by the people who experience anxiety disorders, further limit their treatment (Clement et al., 2015) .
All these factors result in a low use of health services for anxiety disorders. Even in high income countries, only about a third of individuals with anxiety disorders receive any treatment (Alonso et al., 2004; Hamalainen, Isometsa, Sihvo, & Pirkola, 2008) , with the exception of the United States, where treatment rates are considerably higher (Olson, Marcus, Wan, & Geissler, 2004) . Importantly, the proportion of patients with anxiety disorders who receive adequate treatment is still much lower (Kasteenpohja et al., 2016; Roberge et al., 2015) , even in the United States, with less than 15% of people with diagnosed anxiety receiving treatment that conforms with evidence-based recommendations (Kasteenpohja et al., 2016; Roberge et al., 2015) . The treatment gap for anxiety seems to be even wider in low-and middle-income countries (LMICs) (Gureje et al., 2008) , which is consistent with reports for major depressive disorders (MDDs) (Thornicroft et al., 2017) , and for overall mental disorders (Wang et al., 2007a) . In addition, little is known about the access to treatment for anxiety disorders and its adequacy in LMICs. Also different studies have used different definitions of adequate treatment. For minimally adequate pharmacotherapy, any or all of the following criteria have been considered: type, dosage, duration, plus the number of consultations. For minimally adequate psychotherapy, the number of sessions (either 8 or 12) and sometimes the type of therapy (i.e., cognitive behavioral treatment by the same mental health professional) have been proposed (Roberge et al., 2015) .
The World Mental Health (WMH) surveys, including information on anxiety disorders and related treatment across 21 diverse countries worldwide, provide an unprecedented opportunity to examine receipt of treatment for anxiety disorders. On one hand, countries from the whole spectrum of income and geographical variation have been included. On the other, common assessment methods and definitions have been used. The specific objectives of this study were to estimate, among individuals with a 12-month DSM-IV (where DSM is Diagnostic Statistical Manual) anxiety disorder: (i) the proportion who perceived a need for treatment; (ii) the proportion of those who received any treatment; and (iii) the proportion who received possibly adequate treatment. We also examined the influence of comorbidity on perceived need for treatment and whether the latter varied across countries.
It is important to note that in the current DSM5 PTSD is no longer considered an anxiety disorder (as it was in the previous version, the DSM-IV). PTSD is currently considered a different type of disorder and it has been moved to a separate chapter (Trauma and Stress-Related Disorders, DSM-5) (American Psychiatric Association, 2013) . The reader should be aware that the WMH surveys used the DSM-IV classification and therefore we included PTSD among anxiety disorders.
METHODS

Sample
Data came from 23 community epidemiological surveys administered in 21 countries as part of the WMH surveys (Kessler & Ustun, 2004) .
These included 12 surveys carried out in high-income countries, six surveys in upper-middle-income countries, and six in low-or lowermiddle-income countries (see Table 1 ). The majority of surveys were based on nationally representative household samples. Three were representative of urban areas in their countries (Colombia, Mexico, and Peru). Three were representative of selected regions in their countries (Japan, Nigeria, and Murcia, Spain). Four were representative of selected Metropolitan Areas (Sao Paulo, Brazil; Medellin, Colombia; and Beijing-Shanghai and Shenzhen in the People's Republic of China (PRC)). Trained lay interviewers conducted face-to-face interviews with respondents, aged 18 years and over. The interviews took place within the households of the respondents. To reduce respondent burden, the interview was divided into two parts. Part I assessed core mental disorders and was administered to all respondents. Part II, which assessed additional disorders and correlates, was administered to all Part I respondents who met lifetime criteria for any disorder plus a probability subsample of other Part I respondents. Part II data, the focus of this report, were weighted by the inverse of their probabilities of selection into Part II and additionally weighted to adjust samples to match population distributions on the cross-classification of key sociodemographic and geographic variables. Further details about WMH sampling and weighting are available elsewhere (Heeringa et al., 2008) . Response rates ranged between 45.9 and 97.2% and had a weighted average of 70.1% across all surveys.
Measures
Mental disorders
Mental disorders were assessed using the WHO Composite International Diagnostic Interview (CIDI) Version 3.0, a fully structured interview generating lifetime and 12-month prevalence estimates. c Most WMH surveys are based on stratified multistage clustered area probability household samples in which samples of areas equivalent to counties or municipalities in the United States were selected in the first stage followed by one or more subsequent stages of geographic sampling (e.g., towns within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled household resident could not be interviewed. These household samples were selected from Census area data in all countries other than France (where telephone directories were used to select households) and the Netherlands (where postal registries were used to select households). d Argentina, Brazil, Colombia-Medellin, Iraq, Israel, Japan, Romania, and Spain-Murcia did not have an age restricted Part 2 sample. All other countries, with the exception of Nigeria and PRC (B-WMH; S-WMH), (which were age restricted to ≤ 39) were age restricted to ≤ 44. e The response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 71.3%. 
12-month Mental Health Service use
Within disorder-specific sections of the survey, respondents were asked whether or not they ever talked to a medical doctor or other professional (including psychologists, counselors, spiritual advisors, It is important to note that social workers or counselors in the nonmedical treatment group only refer to those working outside of the health services settings. Those working in a specialized or a primary care setting were included in their respective categories (specialized or primary care).
We also asked participants to report whether they felt they needed professional treatment for their mental health problems.
Those responding yes and those reporting using mental health services in the previous 12 months were considered to perceive a need for health care.
Socioeconomic characteristics
To assess educational attainment, respondents were asked how many years of education they completed. As educational levels and systems varied across countries, responses were divided into four groups based on country-specific distributions. Annual family income was classified into quartiles as related to within-country median values of income per family member before taxes.
Analysis
The analyses reported here focus on respondents who met DSM-IV criteria for any anxiety disorder at some time in the 12 months before interview. The definition used for possibly adequate treatment was that of Wang et al. (2007a) , and Thornicroft et al. (2017) 
Statistical analyses
Survey sampling weights were applied in all analyses so that respondents reflected nationally representative samples in terms of sociodemographic characteristics within each country. Standard errors were estimated using the Taylor series linearization method implemented in the SAS software survey procedures to adjust weighting and clustering. To test for differences between high-income, upper-middleincome, and lower-middle-and low-income country groups, in relation to the key variables of interest related to the aims of the paper, chisquare tests were applied. Statistical significance was evaluated using two-sided .05 level tests.
RESULTS
The characteristics of the study sample and survey response rates are presented in Table 1 . In total, 17 nationally representative surveys and six large regionally representative samples were analyzed, with a total of 51,547 Part II respondents (12,285 from low-, 12,598 from middleupper-, and 26,664 from high-income countries). The overall weighted response rate was 71.3%.
As shown in Table 2 (first column), a total of 9.8% of respondents met criteria for at least one anxiety disorder in the 12 months prior to the interview. Prevalence figures were similar for high-income (10.3%) and upper-middle-income (10.6%) countries, but lower for low/lowermiddle-income countries (7.9%). The United States (19.0%) and the metropolitan area of Sao Paulo (18.0%) were the sites with the highest 12-month prevalence, whereas Beijing/Shanghai (3.0%), Israel (3.6%), Nigeria (4.2%), and Japan (4.5%) had the lowest prevalence (Table 2, first column). A full account of the prevalence of anxiety disorders in the WMH surveys may be found in previous publications (Demyttenaere et al., 2004; Kessler & Ustun, 2008) .
TA B L E 2 Twelve-Month Prevalence of DSM-IV Anxiety
Because our study was based on a community dwelling population, we could estimate the proportion of all the individuals meeting DSM-IV diagnostic criteria for any anxiety disorders in the overall population who received any treatment (Table 2 , column 2). This was just over a quarter (27.6%, ranging from 36.3% in high-income countries to 13.1% in low/middle-income countries). The proportion of respondents with an anxiety disorder who received possibly adequate treatment was 9.8% (ranging from 13.8% in high-income to 2.3% in low/middle-income countries) ( Table 2 , column 3).
On average, less than half (41.3%) of the individuals with anxiety disorders reported a need for treatment ( Table 3 presents similar data to those in Table 2 , but stratified by two groups: (1) individuals with anxiety disorders without other comorbid mental disorders (Table 3 , upper section) and (2) those with an anxiety disorder who also had a comorbid mental disorders (Table 3 , lower section). Among those without comorbidity, perception of need for treatment was considerably lower than among those with comorbidity (overall, 26.3 vs. 55.2%, P < .001), Service use among those with a perception of need, however, was similar among those without and those with mental comorbidity (62.7 and 68.6%, respectively). Among individuals who perceived a need for help, the proportion receiving possibly adequate treatment varied among those without comorbidity and those with comorbidity (20.5 and 34.5%, respectively, P < .001). These trends are present in all country income level groups.
For ease of presentation, statistical testing of results for Tables 2   and 3 are presented in supplementary Tables S1 (test results for   Table 2 ) and S2 (test results for Table 3 ). Table S1 shows that statistical tests of comparisons across all country surveys and comparisons across the income groups were all significant in both tables; differences within high-income countries were all significant for all analyses;
tests for within-group comparisons of other country income groups were also significant, with the exception of within-group comparisons of lower/lower-middle-income countries for any treatment (column 2, Table S1 ); and for the same comparison within upper-middle-income countries for possibly adequate treatment among those perceiving need of treatment (column 3, Table S1 ). 
DISCUSSION
A major finding of this study is that across 21 countries worldwide, These results must be considered in the light of several study limitations. First, diagnoses of anxiety disorders were based on the CIDI 3.0. Although acceptable agreement between CIDI diagnoses and diagnoses made during blind clinical reinterviews (Haro et al., 2006) was achieved, these studies were conducted almost exclusively in high-income countries. It remains possible that the accuracy of CIDI anxiety diagnoses could vary in lower-income countries. Second we used the DSM-IV classification that considered PTSD an anxiety disorder. There is a need to further evaluate the anxiety treatment gap using DSM-5 criteria. Third, we relied on self-reported data for use of services, and we were not able to corroborate responses with administrative records. Accuracy of self-reported use of services may differ across sociodemographic and cultural groups and this might affect the comparisons across countries (Luck, 1996; Mann et al., 1992 Additionally, we did not consider severity of anxiety disorder, which could have allowed to estimate whether international differences in use of services are influenced by variation in severity of anxiety disorders. We also used a broad definition of possibly adequate treatment. On one hand, this definition did not include specific effective psychotherapeutic techniques, such as mindfulness meditation (Vollestad, Nielsen, & Nielsen, 2012) , which could have led to an underestimation of adequacy. In fact, it is difficult to determine the adequacy of CAM simply by the number of sessions. And, in relation to pharmacotherapy, we did not consider the type of medication. On the other hand, adequacy of benzodiazepines for treatment for anxiety disorders has been questioned (Baldwin et al., 2014) . Not having excluded them might have led us to overestimate the adequacy of pharmacological treatment. However, even with this inclusion our estimated coverage rates are rather low. Another limitation is that we evaluated service use over a 1-year period. This might underestimate utilization of services in the longer run, as there is some evidence that individuals with persistent symptoms of common mental disorders tend to use services if followed for a longer period than one year (Baldwin et al., 2014) . Also, even though the WMH surveys included a large number of respondents, for some specific subanalyses, the number of respondents included for some countries was small, rendering results less stable and reliable. In addition, a more detailed analysis about use of psychopharmacology and psychotherapy treatments was not possible due to limitations in the way information was collected.
Finally, while results show that a significant proportion of individuals with anxiety disorders do not perceive a need for treatment, our analyses do not allow us to draw conclusions about the specific barriers that may be contributing to the treatment gap for anxiety disorders. A number of different barriers (i.e., stigma, logistical, among others) have been described (Gulliver, Griffiths, & Christensen, 2012) in the literature. We have not have analyzed them and we consider it very important to gather additional information to understand the role that different types of barriers to mental health treatment play in the anxiety treatment gap.
Notwithstanding these limitations, an important treatment gap for anxiety disorders has been identified. This finding is consistent with previous studies, and it suggests that the treatment gap for anxiety disorders is even higher than that described for MDD (Thornicroft et al., 2017) . A lower proportion of individuals with anxiety disorders perceive a need for treatment (41.3% in our study) when compared to those with depression (56.7% in Thornicroft et al. study) . Also, the proportion of those who receive treatment is lower among individuals with anxiety disorders than among those with depression. And the average delay between onset of the disorder and seeking treatment is much longer for anxiety disorders than for MDD (Wang et al., 2007b) .
Finally, the proportion receiving possibly adequate treatment is also lower for those with anxiety disorders (9.8%) and considerably lower than for those with MDD (16.5%) (Thornicroft et al., 2017) . Differences in the severity of symptoms may contribute to differences in utilization rates. In our study, mental disorder comorbidity shows an important association with perception of need for care. This is likely due to a higher severity of symptoms among persons with comorbid anxiety (Saris, Aghajani, van der Werff, van der Wee, & Penninx, 2017) . There is also the possibility that some symptoms are not recognized as a mental disorder, but rather are attributed to somatic illnesses. This might be an issue for the cross-cultural validity of some diagnoses, as has been pointed out for PTSD (Hinton & Lewis-Fernandez, 2011 ). There is a need to research the factors and mechanisms shaping perception of need for services.
In addition to lack of perceived need for treatment, other barriers may also play an important role. Low recognition rates for anxiety disorders have been described at the primary care level (Olariu et al., 2015 ). Also, the low level of perceived need for care among individuals with anxiety disorders may be due to low levels of mental health literacy (Ho et al., 2008; Wang et al., 2007b) . Efforts in both areas (i.e., increasing detection rates in primary care and in awareness of the potential benefits of existing therapies among the public) are needed.
A worrying finding of our study is the low proportion of possibly adequate treatment for anxiety disorders. Our data indicate that this may result from a combination of the generally low levels of perception of need for care, together with varying level of access to care
as well as differences in the quality of care provided. In this respect, 
